Methipred-2 5pcs

Presentation
Methipred 2 Tablet: Each film coated tablet contains Methylprednisolone USP 2 mg.
Methipred 4 Tablet: Each film coated tablet contains Methylprednisolone USP 4 mg.
Methipred 8 Tablet: Each film coated tablet contains Methylprednisolone USP 8 mg.
Methipred 16 Tablet: Each film coated tablet contains Methylprednisolone USP 16 mg.
Description
Methylprednisolone is a potent anti-inflammatory steroid. It has greater anti-inflammatory potency than Prednisolone, even less
tendency than Prednisolone to induce sodium and water retention. The relative potency of Methylprednisolone to Hydrocortisone is
at least four to one.
Pharmacodynamic Properties
Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. Glucocorticoids
primarily bind to and activate intracellular glucocorticoid receptors that being activated bind to promoter regions of DNA (which
may activate or suppress transcription) and activate transcription factors that results in inactivation of genes through deacetylation of
histones. Methylprednisolone influences the kidney and fluid & electrolyte balance, lipid, protein, and carbohydrate metabolism,
skeletal muscle, the cardiovascular system, the immune system, the nervous system, and the endocrine system.
Pharmacokinetic Properties
The absolute bioavailability of Methylprednisolone is generally high (82% to 89%) following oral administration and rapidly
absorbed and the maximum plasma concentration is achieved around 1.5 to 2.3 hours across doses following oral administration in
normal healthy adults. Methylprednisolone is widely distributed into the tissues and its volume of distribution is 41-61.5 L. It crosses
the blood-brain barrier and the placental barrier and is secreted in breast milk. The plasma protein binding of Methylprednisolone
in humans is approximately 77%. Methylprednisolone is metabolized in the liver to inactive metabolites. No dosing adjustments are
necessary in renal failure. Methylprednisolone is haemodializable.
Indications
1. Endocrine Disorders: Primary or Secondary Adrenocortical Insufficiency, Congenital Adrenal Hyperplasia, Nonsuppurative
Thyroiditis, Hypercalcemia associated with Cancer; 2. Rheumatic Disorders: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis,
Ankylosing Spondylitis, Acute and Subacute Bursitis, Synovitis of Osteoarthritis, Acute nonspecific Tenosynovitis, Post-traumatic
Osteoarthritis, Psoriatic Arthritis, Epicondylitis, Acute Gouty Arthritis; 3. Collagen Diseases: Systemic Lupus Erythematosus, Systemic
Dermatomyositis and Acute Rheumatic Carditis, 4. Dermatologic Diseases: Bullous Dermatitis Herpetiformis, Severe Erythema
Multiforme (Stevens-Johnson syndrome), Severe Seborrheic Dermatitis, Exfoliative Dermatitis, Mycosis Fungoides, Pemphigus,
Severe Psoriasis, 5. Allergy: Seasonal or Perennial Allergic Rhinitis, Drug hypersensitivity reactions, Serum Sickness, Contact
Dermatitis, Bronchial Asthma and Atopic Dermatitis; 6. Ophthalmic Diseases: Allergic Corneal Ulcers, Herpes Zoster Ophthalmicus,
Anterior segment inflammation, Sympathetic Ophthalmia, Keratitis, Optic Neuritis, Allergic Conjunctivitis, Chorioretinitis, Iritis and
Iridocyclitis; 7. Respiratory Dieseases: Symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis,
Aspiration Pneumonitis; 8. Hematological Disorders: Idiopathic Thrombocytopenic Purpura in adults, Secondary Thrombocytopenia
in adults, Acquired (Autoimmune)Hemolytic Anemia, Erythroblastopenia, Congenital (Erythroid) Hypoplastic Anemia; 9. Neoplastic
Diseases: For palliative management of Leukemias and Lymphomas in adults, Acute Leukemia of childhood; 10. Edematous states:
To induce a Diuresis or remission of Proteinuria in the Nephrotic Syndrome, without Uremia, of the idiopathic type or that due to
Lupus Erythematosus; 11. Gastrointestinal Disease: To tide the patient over a critical period of the disease in Ulcerative Colitis &
Regional Enteritis 12. CNS Disease: Acute Exacerbations of Multiple Sclerosis.
Dosage and Administration
The usual range is 2-48 mg daily in divided doses, depending on the specific disease being treated.
As anti-inflammatory/immunosuppressive initial dosage: As anti-inflammatory/immunosuppressive, the initial dosage of
Methylprednisolone tablets may vary from 4- 48 mg per day depending on the specific disease entity being treated. In situations of
less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage
should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of
satisfactory clinical response, Methylprednisolone should be discontinued and the patient transferred to other appropriate therapy. It
should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under
treatment and the response of the patient.
As anti-inflammatory/immunosuppressive maintenance dosage: After a favorable response is noted, the proper maintenance dosage
should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest
dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed
in regard to drug dosage. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually
rather than abruptly.
Multiple Sclerosis: In the treatment of acute exacerbations of multiple sclerosis, daily doses of 160 mg of Methylprednisolone for a
week followed by 64 mg every other day for 1 month have been shown to be effective.
Methylprednisolone 4 mg tablet can be used to treat and to control severe allergy and dermatitis following the guideline listed
below to minimize the steroid withdrawal syndromes:
• Day 1: 2 tablets before breakfast + 1 tablet after lunch + 1 tablet after dinner + 2 tablets at bedtime
• Day 2: 1 tablet before breakfast + 1 tablet after lunch + 1 tablet after dinner + 2 tablets at bedtime
• Day 3: 1 tablet before breakfast + 1 tablet after lunch + 1 tablet after dinner + 1 tablet at bedtime
• Day 4: 1 tablet before breakfast + 1 tablet after lunch + 1 tablet at bedtime
• Day 5: 1 tablet before breakfast + 1 tablet at bedtime
• Day 6: 1 tablet before breakfast